Extra-Renal manifestations of atypical hemolytic uremic syndrome in children

  • Kibriya Fidan
  • Nilüfer Göknar
  • Bora Gülhan
  • Engin Melek
  • Zeynep Y. Yıldırım
  • Esra Baskın
  • Mutlu Hayran
  • Kaan Gülleroglu
  • Zeynep B. Özçakar
  • Fatih Ozaltin
  • Oguz Soylemezoglu
Original Article



Atypical hemolytic uremic syndrome (aHUS) is a chronic disease characterized by thrombotic microangiopathy and a high risk of end-stage kidney disease. Dysregulation and/or excessive activation of the complement system results in thrombotic microangiopathy. Interest in extrarenal manifestations of aHUS is increasing. This study aimed to determine the clinical characteristics of patients with extrarenal manifestations of aHUS in childhood.


This study included 70 children with extrarenal manifestations of HUS from the national Turkish aHUS Registry. The demographics, clinical characteristics, genetic test results, all treatments, and renal/hematologic status of aHUS patients with extrarenal involvement were recorded.


The most common extrarenal manifestation was neurological system involvement (n = 46 [27.2%]), followed by gastrointestinal (n = 20 [11.8%]), cardiovascular (n = 12 [7%]), and respiratory (n = 12 [7%]) involvement. The patients with neurological involvement had a higher mortality rate and a lower estimated glomerular filtration rate (eGFR) than the other patients at last follow-up. Eculizumab (with or without plasma exchange/plasma infusion) treatment increased the renal and hematologic recovery rates.


The most common and serious extrarenal manifestation of aHUS is neurological involvement and treatment outcome findings presented herein are important to all relevant clinicians.


Atypical hemolytic uremic syndrome Children Neurological involvement Extrarenal involvement Eculizumab 



Atypical hemolytic uremic syndrome


Thrombotic microangiopathy


Diacylglycerol kinase-ε




Central nervous system


Posterior reversible encephalopathy syndrome



This study was supported by the Hacettepe University Scientific Research and Development Office (grant no. 010A101009).

Author contribution

Kibriya Fidan, Nilufer Goknar, and Oguz Soylemezoglu participated in conception, design, analysis and interpretation of data, drafting the article, and revising. Kaan Gülleroğlu, Esra Baskın, Engin Melek, Zeynep Y. Yıldırım, Bora Gülhan, and Zeynep Birsin Özçakar participated in data collection. Fatih Özaltın participated in study design and evaluation of genetic results. All authors contributed to manuscript development and approved the final manuscript.

Compliance with ethical standards

The study protocol was approved by the Hacettepe University Ethics Committee (FON10/03-22) and written informed consent was obtained from the parents of each patient.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Rosove MH (2014) Thrombotic microangiopathies. Semin Arthritis Rheum 43(6):797–805CrossRefPubMedGoogle Scholar
  2. 2.
    Loirat C, Fremaux-Bacchi V (2011) Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 6:60CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676–1687CrossRefPubMedGoogle Scholar
  4. 4.
    Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5(10):1844–1859CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lemaire M, Femeaux Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji W, Overton JD, Mane SM, Nürnberg G, Altmüller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, Nürnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP (2013) Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45(5):531–536CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ozaltin F, Li B, Rauhauser A, An SW, Soylemezoglu O, Gonul II, Taskiran EZ, Ibsirlioglu T, Korkmaz E, Bilginer Y, Duzova A, Ozen S, Topaloglu R, Besbas N, Ashraf S, Du Y, Liang C, Chen P, Lu D, Vadnagara K, Arbuckle S, Lewis D, Wakeland B, Quigg RJ, Ransom RF, Wakeland EK, Topham MK, Bazan NG, Mohan C, Hildebrandt F, Bakkaloglu A, Huang CL, Attanasio M (2013) DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol 24(3):377–384CrossRefPubMedGoogle Scholar
  7. 7.
    Bu F, Maga T, Meyer NC (2014) Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 25:55–64CrossRefPubMedGoogle Scholar
  8. 8.
    Hofer J, Rosales A, Fischer C, Giner T (2014) Extra renal manifestations of complement mediated thrombotic microangiopathies. Front Pediatr 2:97CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Frieling M, Karpman D, Landau D, Langman C, Licht C, Pecoraro C, Riedl M, Siomou E, van de Kar N, Walle JV, Loirat C, Taylor CM (2014) An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol 29:1967–1978CrossRefPubMedGoogle Scholar
  10. 10.
    Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554–562CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Besbas N, Gulhan B, Soylemezoglu O, Ozcakar ZB, Korkmaz E, Hayran M, Ozaltin F (2017) Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol 18:6CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Koehl B, Boyer O, Biebuyck-Gouge N, Kossorotoff M, Frémeaux-Bacchi V, Boddaert N, Niaudet P (2010) Neurological involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol 25:2539–2542CrossRefPubMedGoogle Scholar
  13. 13.
    Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M, International Registry of Recurrent and Familial HUS/TTP (2003) Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 12:3385–3395CrossRefPubMedGoogle Scholar
  14. 14.
    Seddon MJ, Yu Y, Miller EC, Reynolds R, Tan PL, Gowrisankar S, Goldstein JI, Triebwasser M, Anderson HE, Zerbib J, Kavanagh D, Souied E, Katsanis N, Daly MJ, Atkinson JP, Raychaudhuri S (2013) Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet 451:366–370Google Scholar
  15. 15.
    Feng S, Eyler SJ, Zhang Y, Maga T, Nester CM, Kroll MH, Smith RJ, Afshar-Kharghan V (2013) Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood 122:1487–1493CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ (2010) Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 31:1445–1460CrossRefGoogle Scholar
  17. 17.
    Greenbaum LA, Fila M, Ardissino G, Al-Akash S, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar N, Vande Walle J, Massayo O, Bedrosian CL, Licht C (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89(3):701–711CrossRefPubMedGoogle Scholar
  18. 18.
    Vilalta R, Lara E, Madrid A, Chocron S, Muñoz M, Casquero A, Nieto J (2012) Long-term eculizumab improves clinical outcome and in atypical hemolytic uremic syndrome. Pediatr Nephrol 27:2323–2326CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Gulleroglu K, Fidan K, Hançer VS, Bayrakci U, Baskin E, Soylemezoglu O (2013) Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 28:827–830CrossRefPubMedGoogle Scholar
  20. 20.
    Hu H, Nagra A, Haq MR, Gilbert R (2014) Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurolocal involvement. Pediatr Nephrol 29:1103–1106CrossRefPubMedGoogle Scholar
  21. 21.
    Barnett ND, Kaplan AM, Bernes SM, Cohen ML (1995) Hemolytic uremic syndrome with particular involvement of basal ganglia and favorable outcome. Pediatr Neurol 12(2):155–158CrossRefPubMedGoogle Scholar
  22. 22.
    Baskin E, Gulleroglu K, Kantar A, Bayrakci U, Ozkaya O (2015) Success of eculizumab in the treatment of atypical hemolytic uremic syndrome. Pediatr Nephrol 30:783–789CrossRefPubMedGoogle Scholar
  23. 23.
    Ohanian M, Cable C, Halka K (2011) Eculizumab safely reverses neurologic impairment and eliminated need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol 3:5–12PubMedPubMedCentralGoogle Scholar
  24. 24.
    Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Frémeaux-Bacchi V, HUS International (2016) An international consensus approach to the management of atypical haemolytic uremic syndrome in children. Pediatr Nephrol 31:15–39CrossRefPubMedGoogle Scholar
  25. 25.
    Geerdink LM, Westra D, Wijk V, Dorresteijn EM, Lilien MR, Davin JC, Kömhoff M, Van Hoeck K, van der Vlugt A, van den Heuvel LP, van de Kar NC (2012) Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 27:1283–1291CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Noris M, Remuzzi G (2014) Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 10:174–180CrossRefPubMedGoogle Scholar
  27. 27.
    Sallee M, Daniel L, Piercecchi MD, Jaubert D, Fremeaux-Bacchi V, Berland Y, Burtey S (2010) Myocardial infarction is a complication of factor-H associated atypical HUS. Nephrol Dial Transplant 25:2028–2032CrossRefPubMedGoogle Scholar
  28. 28.
    Losito A, Pittavini L, Covarelli C (2012) Thrombotic microangiopathic nephropathy, pulmonary hypertension and nephromegaly: case report of a patient treated with endothelin receptor antagonist. Clin Nephrol 77:164–170CrossRefPubMedGoogle Scholar
  29. 29.
    Malina M, Gulati A, Bagga A, Majid MA, Simkova E, Schaefer FMalina M, Gulati A, Bagga A, Majid MA, Simkova E, Schaefer F (2013) Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics 131(1):331–335CrossRefGoogle Scholar

Copyright information

© IPNA 2018

Authors and Affiliations

  • Kibriya Fidan
    • 1
  • Nilüfer Göknar
    • 2
  • Bora Gülhan
    • 3
  • Engin Melek
    • 4
  • Zeynep Y. Yıldırım
    • 5
  • Esra Baskın
    • 6
  • Mutlu Hayran
    • 3
  • Kaan Gülleroglu
    • 6
  • Zeynep B. Özçakar
    • 7
  • Fatih Ozaltin
    • 3
    • 8
  • Oguz Soylemezoglu
    • 1
  1. 1.Gazi University, School of Medicine, Department of Pediatric NephrologyIstanbulTurkey
  2. 2.Bezmialem Vakif University, School of Medicine, Department of Pediatric NephrologyIstanbulTurkey
  3. 3.Hacettepe University, School of Medicine, Department of Pediatric NephrologyAnkaraTurkey
  4. 4.Cukurova University, School of Medicine, Department of Pediatric NephrologyAnkaraTurkey
  5. 5.Istanbul University, School of Medicine, Department of Pediatric NephrologyIstanbulTurkey
  6. 6.Baskent University, School of Medicine, Department of Pediatric NephrologyAnkaraTurkey
  7. 7.Ankara University, School of Medicine, Department of Pediatric NephrologyAnkaraTurkey
  8. 8.Nephrogenetics Laboratory, Hacettepe University Faculty of MedicineAnkaraTurkey

Personalised recommendations